Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns
Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”
Paradigm4 has introduced the ‘Precision Cell Atlas’ as an integral component of its REVEAL: SingleCell app. The Precision Cell Atlas enables scientists to create a custom cell atlas by selectively combining an unlimited number of samples from multiple datasets for specific research objectives and explicitly saving them for collaboration, reuse,
Paradigm4 announces the general availability of flexFS, a hyperscale file system designed for AI/ML and large file data workloads, providing unparalleled throughput at 50% lower cost
